Eli Samaha - 06 Jul 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (tbph)

Reporting relationship: 10%+ Owner
Issuer ticker: tbph
Reported as of: 06 Jul 2026
Net transaction value: -$119,397
SEC form: 4
Accepted by SEC: 08 Jul 2026, 16:13:43 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: Eli Samaha

Key filing fact

Eli Samaha filed Form 4 for Theravance Biopharma, Inc. (tbph) on 08 Jul 2026.

Key facts

This page summarizes Eli Samaha's Form 4 filing for Theravance Biopharma, Inc. (tbph).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Jul 2026, 16:13.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$119,397.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001877589 Primary reporting owner

Samaha Eli

Relationship: 10%+ Owner
Address: 150 EAST 58TH ST, STE 1403, NEW YORK
Signature: Eli Samaha
Signature date: 08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

tbph transaction

COM

Sale

Transaction value: $23,856
Shares: -1,400
Change %: -0.02%
Price: $17.04
Shares after: 9,173,053
Date: 06 Jul 2026
Ownership: See Footnotes
Footnotes: F1

tbph transaction

COM

Sale

Transaction value: $95,541
Shares: -5,564
Change %: -0.06%
Price: $17.17
Shares after: 9,167,489
Date: 07 Jul 2026
Ownership: See Footnotes
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

Footnote F2

The sales price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.